Detection of EGFR and KRAS mutations in fine-needle aspirates stored on whatman FTA cards: Is this the tool for biobanking cytological samples in the molecular era?

Cancer Cytopathology

Volumn 118, Issue 6, 2010, Pages 450-456

  Da Cunha Santos, Gilda ^a   Liu, Ni ^b   Tsao, Ming Sound ^a,b   Kamel Reid, Suzanne ^a,b   Chin, Kayu ^a   Geddie, William R ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cytopathology; DNA mutational analysis; EGFR genes; ErbB 1 genes; Fine needle aspiration; K ras genes; Nonsmall cell lung carcinoma; Ras genes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; GENETICS; HEALTH CARE FACILITY; HUMAN; LABORATORY DIAGNOSIS; LUNG TUMOR; METHODOLOGY; MUTATION; NEEDLE BIOPSY; PATHOLOGY; TUMOR CELL LINE;

BIOPSY, FINE-NEEDLE; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPECIMEN HANDLING; TISSUE BANKS;

EID: 79952221486     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20102     Document Type: Article

References (20)

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
2. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent nonsmall-cell lung cancer. J Clin Oncol. 2005;23:6829-6837.
3. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:7232-7241.
4. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis. 1999;20:1507-1510.
5. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
6. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268-4275.
7. Clark DP. Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer (Cancer Cytopathol). 2009;117:289-297.
8. Yamamura M, Makimura K, Ota Y. Evaluation of a new rapid molecular diagnostic system for Plasmodium falciparum combined with DNA filter paper, loop-mediated isothermal amplification, and melting curve analysis. Jpn J Infect Dis. 2009;62:20-25.
9. Muthukrishnan M, Singanallur NB, Ralla K, Villuppanoor SA. Evaluation of FTA cards as a laboratory and field sampling device for the detection of foot-and-mouth disease virus and serotyping by RT-PCR and real-time RT-PCR. J Virol Methods. 2008;151:311-316.
10. de Clare Bronsvoort BM, von Wissmann B, Fevre EM, Handel IG, Picozzi K, Welburn SC. No gold standard estimation of the sensitivity and specificity of 2 molecular diagnostic protocols for Trypanosoma brucei spp. in Western Kenya. PLoS One. 2010;5:e8628.
11. Bereczky S, Martensson A, Gil JP, Farnert A. Short report: rapid DNA extraction from archive blood spots on filter paper for genotyping of Plasmodium falciparum. Am J Trop Med Hyg. 2005;72:249-251.
12. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26:983-994.
13. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007;13:4954-4955.
14. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer (Cancer Cytopathol). 2009;117:67-72.
15. Fukui T, Ohe Y, Tsuta K, et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res. 2008;14: 4751-4757.
16. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol. 2006;126:608-615.
17. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol. 2008;3:527-529.
18. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008;99:929-935.
19. Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol. 1999;155:1467-1471.
20. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25:587-595.